Our leadership team
Adimab’s leadership combines decades of industry experience with scientific excellence and strategic vision, fostering collaboration that drives innovation and lasting partnerships across the biopharma industry.
We set out to bring full-length IgG discovery into a controllable eukaryotic system, combining in vitro speed with eukaryotic quality to deliver better molecules, faster.
For more than 15 years, our unique platform and collaborative model have fueled many successful partnerships, with dozens of programs progressing from discovery into clinical development, proving our approach effectively delivers from idea to clinic.
Our highly controllable in vitro eukaryotic system allows discovery and engineering in the final IgG and HCAb format.
From the start, our approach emphasizes quality and developability, preparing molecules for what comes next.
We integrate multidisciplinary expertise in antibody discovery, protein engineering, analytics, and computation.
Whether through discovery, engineering, or platform transfer, we tailor partnerships to your needs.
We expand what’s possible in human health by enabling the development of transformative protein therapeutics. Through world-class protein engineering and an unwavering commitment to our partners’ success, we help advance science and accelerate the discovery of life-changing medicines that improve and extend lives, and in the process, we are building the industry’s most extensive therapeutic pipeline.
At Adimab, we believe discovery thrives where science meets collaboration. We foster an environment where openness, rigor, and curiosity drive discovery, empowering partners to push boundaries, make bold decisions, and advance programs that shape the future of medicine.
Adimab’s leadership combines decades of industry experience with scientific excellence and strategic vision, fostering collaboration that drives innovation and lasting partnerships across the biopharma industry.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.
Design of orthogonal constant domain interfaces to aid proper heavy/light chain pairing of bispecific antibodies
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.